BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27940128)

  • 1. microRNA-210 overexpression inhibits tumor growth and potentially reverses gemcitabine resistance in pancreatic cancer.
    Amponsah PS; Fan P; Bauer N; Zhao Z; Gladkich J; Fellenberg J; Herr I
    Cancer Lett; 2017 Mar; 388():107-117. PubMed ID: 27940128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
    Fan P; Liu L; Yin Y; Zhao Z; Zhang Y; Amponsah PS; Xiao X; Bauer N; Abukiwan A; Nwaeburu CC; Gladkich J; Gao C; Schemmer P; Gross W; Herr I
    Cancer Lett; 2016 Apr; 373(1):130-137. PubMed ID: 26828016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
    Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
    Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine.
    Liang C; Yu XJ; Guo XZ; Sun MH; Wang Z; Song Y; Ni QX; Li HY; Mukaida N; Li YY
    Oncotarget; 2015 Jun; 6(16):14440-55. PubMed ID: 25971209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
    Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
    Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Ma L; Fan Z; Du G; Wang H
    Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity.
    Oguri T; Achiwa H; Sato S; Bessho Y; Takano Y; Miyazaki M; Muramatsu H; Maeda H; Niimi T; Ueda R
    Mol Cancer Ther; 2006 Jul; 5(7):1800-6. PubMed ID: 16891466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
    Giovannetti E; Funel N; Peters GJ; Del Chiaro M; Erozenci LA; Vasile E; Leon LG; Pollina LE; Groen A; Falcone A; Danesi R; Campani D; Verheul HM; Boggi U
    Cancer Res; 2010 Jun; 70(11):4528-38. PubMed ID: 20460539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
    Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
    PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
    Rajabpour A; Afgar A; Mahmoodzadeh H; Radfar JE; Rajaei F; Teimoori-Toolabi L
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):765-775. PubMed ID: 28887583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic nicotine inhibits the therapeutic effects of gemcitabine on pancreatic cancer in vitro and in mouse xenografts.
    Banerjee J; Al-Wadei HA; Schuller HM
    Eur J Cancer; 2013 Mar; 49(5):1152-8. PubMed ID: 23146955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-136-5p regulates gemcitabine resistance in pancreatic cancer via down-regulating ZNF32.
    Xu Y; Qin Y; Cui JX; Xu J
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10472-10482. PubMed ID: 33155203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
    Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
    Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
    Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
    Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Tadros S; Shukla SK; King RJ; Gunda V; Vernucci E; Abrego J; Chaika NV; Yu F; Lazenby AJ; Berim L; Grem J; Sasson AR; Singh PK
    Cancer Res; 2017 Oct; 77(20):5503-5517. PubMed ID: 28811332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-29c Increases the Chemosensitivity of Pancreatic Cancer Cells by Inhibiting USP22 Mediated Autophagy.
    Huang L; Hu C; Cao H; Wu X; Wang R; Lu H; Li H; Chen H
    Cell Physiol Biochem; 2018; 47(2):747-758. PubMed ID: 29807360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
    Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.